It was previously shown that carvedilol, a b-adrenergic receptor antagonist with antioxidant properties, was able to inhibit the mitochondrial permeability transition (MPT). In the present work, the hypothesis was that the negative impact of carvedilol on the MPT was specifically the result of its antioxidant effect. For the current investigation, we used three different MPT inducers.
Introduction
The mitochondrial inner membrane permeability can increase owing to a calcium-dependent phenomenon known as the mitochondrial permeability transition (MPT), which is caused by the formation of pores of protein nature (mitochondrial permeability transition pores [MPTP] ). Agents like phosphate, pro-oxidant systems like t-butylhydroperoxide or xanthine oxidase plus hypoxanthine, and thiol crosslinkers, such as phenylarsine oxide or carboxyatractyloside (a conformational inhibitor of the adenine nucleotide translocator [ANT]), are known to decrease the calcium threshold for MPT induction (1) . During cardiac ischemia and reperfusion, heart mitochondria suffer from increased oxidative injury and accumulation of calcium and phosphate (2, 3) . MPT activation by oxidative stress and the protection afforded by antioxidants has already been demonstrated in several studies (4) (5) (6) . The role of the MPT on myocyte reperfusion injury is well established and was proposed to be determinant for the fate of the cardiac cell (7, 8) .
Physiologically, the so-called "low-conductance" state of the MPTP would be useful in releasing excessive calcium accumulation in the mitochondrial matrix. Also, by keeping the mitochondrial transmembrane electric potential (DY) within the normal range, membrane hyperpolarization is avoided (9, 10) . The transition to a "high-conductance" state depends on the saturation of calcium-binding sites. This state would also be responsible for a permanent ATP deficit, leading to cell necrosis (11) . The characterization of the MPT in high-and low-conductance forms is still a very controversial subject.
Carvedilol is clinically used for the treatment of congestive heart failure, mild-to-moderate hypertension, and myocardial infarction (12) . Carvedilol competitively blocks b 1 , b 2 , and a 1 -adrenoceptors, thereby showing a marked vasodilating property. Carvedilol antioxidant properties, which are responsible for an additional cardioprotective impact not shared by other b-adrenoceptor antagonists (13, 14) , was also previously established. The potential role of the antioxidant properties of carvedilol in the prevention of apoptotic cell death has been reported (15) . The protective effects of carvedilol on ischemic heart disease may be predominantly from the protection of mitochondrial function (16) (17) (18) (19) (20) .
In a recent work (20) , we showed that carvedilol acted as a dose-dependent inhibitor of the high-conductance state of the MPT when this condition was induced by calcium and phosphate on isolated heart mitochondria. These conclusions were supported not only by observing that carvedilol prevented mitochondrial swelling in a sucrose, not in a KCl-based buffer, but also by demonstrating the inability of carvedilol to prevent calcium-induced depolarization of the mitochondrial membrane, in opposition to preventing mitochondrial swelling. We proposed that the prevention afforded by carvedilol against the oxidation of mitochondrial protein thiol groups was the main mechanism by which carvedilol inhibited the MPT (20) . However, a key question arose: Could the proposed mechanism also apply to other MPT inducers? In other words, are the intrinsic antioxidant properties of carvedilol fundamental for its effect regarding inhibition of the MPT?
To answer these two questions, we induced the MPT on isolated heart mitochondria with three different inducing systems, one of which was calcium and phosphate (the classical inducers, repeated in this article). We also used calcium plus t-butylhydroperoxide (tBHP), an agent that induces oxidative stress inside mitochondria, and calcium plus carboxyatractyloside, a compound that acts directly on one of the pore components (the ANT). Each system is known to induce the MPT with different mechanisms and dependence of protein thiol oxidation.
Using the highest carvedilol concentration tested in our previous work (20 µM [20] ), we tested the impact of carvedilol on several MPT hallmarks and on the oxidation of mitochondrial protein thiol groups. Cyclosporin-A was crucial for determining the relevance of the primary oxidation of protein thiol groups for MPT induction, as cyclosporin-A inhibits the MPT independently of antioxidant mechanisms.
These results allowed the conclusion that carvedilol is effective when an oxidative phenomenon oxidizes protein thiol groups and causes MPT induction, thus revealing the importance of the antioxidant properties of carvedilol.
Materials and Methods

Materials
Carvedilol was obtained from Roche Portugal (Amadora, Portugal) and was prepared in dimethylsulfoxide (DMSO). The DMSO volumes used were minimal (around 0.1% final volume) and had no effect whatsoever on the results described in this paper (data not shown). Calcium Green 5-N was obtained from Molecular Probes (Eugene, OR). All other compounds were purchased from Sigma Chemical Co. (St. Louis, MO).
Animals
Male Wistar rats (250-300 g), housed at 22-24°C under artificial light for 12-h light/day cycle and with access to water and food ad libitum, were used throughout the experiments. The research procedure was carried out in accordance with the European Requirement for Vertebrate Animal Research.
Isolation of Mitochondria from Rat Heart
Rat heart mitochondria from male Wistar rats (250-300 g) were isolated as previously described (17) . The protease-based method yields a mix population of subsarcolemal and interfibrillar mitochondria.
Mitochondrial protein content was determined by the biuret method, calibrated with bovine serum albumin.
Determination of Mitochondrial Swelling
We followed changes in mitochondrial volume by monitoring the decrease in absorbance at 540 nm with a Jasco V-560 spectrophotometer. Reactions were carried out at 25°C, in 2 mL of the standard buffer (200 mM sucrose, 10 mM TRIS-MOPS, 10 µM EGTA, and 5 mM KH 2 PO 4 , pH 7.4) supplemented with 1 mg mitochondria. Mitochondrial energization was obtained with 8 mM succinate (plus 4 µM rotenone). Carvedilol was preincubated with the mitochondrial suspension for 3 min before mitochondrial energization. Cyclosporin-A was incubated with the mitochondrial suspension prior to calcium addition.
Calcium Accumulation by Heart Mitochondria
Extramitochondrial free Ca 2+ was measured with the hexapotassium salt of the fluorescent probe Calcium Green 5-N. Heart mitochondria (0.2 mg) were resuspended in 2 mL buffer containing 200 mM sucrose, 10 mM TRIS-MOPS, 10 µM EGTA, 1 mM KH 2 PO 4 , 7.4, 8 mM succinate, and 4 µM rotenone. Free Ca 2+ was monitored with 100 nM Calcium Green 5-N. Fluorescence was continuously recorded in a water-jacketed cuvet holder at 25°C with a PerkinElmer LS-50B fluorescence spectrometer with excitation and emission wavelengths of 506 and 531 nm, respectively. At the end of each experiment, a calibration was performed for calculating the maximum and minimum fluorescence signal, with an excess of calcium and EGTA, respectively. The used dissociation constant for the complex Ca 2+ -probe was 4 µM (21) .
For experiments concerning rate and amount of calcium accumulated by mitochondria, we suspended heart mitochondria (1 mg) in 2 mL buffer containing 200 mM sucrose, 10 mM TRIS-MOPS, 10 µM EGTA, 5 mM KH 2 PO 4 , 4 µM rotenone, and 8 mM succinate. Free Ca 2+ was monitored with 200 nM Calcium Green 5-N. A pulse of 100 µM calcium was added. From the fluorescent decay (calcium entry to mitochondria) and with proper calibration (as described previously), we determined the rate of calcium uptake. After calcium accumulation, we added 1 µM FCCP to dissipate mitochondrial DY and to release all accumulated calcium. Values pre-and post-FCCP addition were taken and proper calibration was used to determine the total amount of accumulated calcium.
Determination of Mitochondria Protein Thiol Content
To determine the antioxidant protective effect of carvedilol on mitochondrial protein thiol groups, we used a variation of Ellman's method (22), as already described (20) . Results are presented as a percentage of control owing to variations in the control values. Heart mitochondria (0.5 mg/mL) were incubated with carvedilol and cyclosporin-A for 3 min before the addition of inducers. The reaction ran for 30 min at 25°C, and the oxidation of protein thiol groups was determined.
Statistical Analysis
The results are presented as mean ± SEM of at least five independent preparations. Statistical analyses were performed using ANOVA plus a Newman-Keuls posttest. A value of p < 0.05 was considered statistically significant.
Results
To study the effects of carvedilol, we previously conducted preliminary experiments to determine the minimum concentrations of the reagents that induce the maximal effect for each experimental set-up (either mitochondrial swelling or calcium-induced calcium release; data not shown). The occurrence of large amplitude swelling follows the opening of the high-conductance state of the MPT. Panel A of Fig. 1 shows the occurrence of large amplitude mitochondrial swelling after a 500 µM calcium pulse (trace D) and in the presence of 1 µM cyclosporin-A (trace A) and 20 µM carvedilol (trace C). High concentrations of calcium were used, as heart mitochondrial preparations are extremely resistant to calcium loading in the absence of any potent pro-oxidant agent (Oliveira et al., unpublished results and ref. 7). Furthermore, Fontaine and collaborators (23) described how the calcium threshold for MPTP opening is highly increased in succinate-energized mitochondria in the presence of rotenone. This finding also explains the increase in absorbance that fol-
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Humana Press Volume 4, 2004 lowed calcium addition. As described elsewhere, the formation of calcium-phosphate complexes in the mitochondrial matrix causes a transient increase in the suspension absorbance (24) . As seen, cyclosporin-A inhibited calcium-induced mitochondrial swelling, and carvedilol was able to greatly reduce mitochondrial swelling amplitude. (panel C, trace A) . In opposition, 20 µM carvedilol had no inhibitory effect (an increase in the rate of swelling was even consistently observed in most of the assays) (panel C, trace C). Strangely enough, in the presence of cyclosporin-A (panel C, trace A), the absorbance values increased, which suggests mitochondrial shrinkage. We are unable to find a logical explanation for this phenomenon.
Direct measurements of calcium uptake and release were obtained by using an extra-mitochondrial fluorescent calcium-sensitive probe (Fig. 2) . Calcium addition to succinate-energized mitochondria caused a rapid increase of fluorescence, followed by a gradual decrease, which was indicative of mitochondrial calcium entry (Fig. 2, panels A-C) .
Mitochondria were not able to fully accumulate calcium (panel A, trace B). Full accumulation was attained only in the presence of cyclosporin-A (panel A, trace A). Carvedilol delayed the loss of mitochondrial calcium loading capacity (panel A, trace C). By using a smaller calcium pulse, mitochondria were now able to accumulate it inside (panel B, trace B), although a slow release was observable near the 
Humana Press Volume 4, 2004 end of the experiment. Soon after calcium accumulation, the addition of tBHP forced a calcium discharge, with an initial period of slow calcium release (panel B, trace D). Cyclosporin-A inhibited tBHP-induced calcium release (panel B, trace A), while carvedilol had a marginal (but consistent in the five experiments) delay effect on tBHP-induced calcium release. By exchanging tBHP for carboxyatractyloside, we had similar results, with the exception of the inability of carvedilol to inhibit the phenomenon. The effect of carvedilol and cyclosporin-A was evaluated concerning the inhibition of the oxidation of protein thiol groups (P-SH groups). Values are presented as a percentage of control, as there were some fluctuations concerning the control value and, hence, the need to normalize the data to each day's control value. Panels A-C of Fig. 3 show the comparisons with control values (no additions to mitochondria). Mitochondrial incubation with 500 µM calcium caused a decrease of P-SH groups (panel A). This decrease was partly prevented by carvedilol (20 µM) and cyclosporin-A. In the absence of calcium, Carvedilol had no effect.
We also observed a reduction in the mitochondrial content of P-SH groups when mitochondria were incubated with calcium (100 µM) and tBHP (1 mM). A small decrease was also observed with calcium alone (100 µM, panel B). Cyclosporin-A and carvedilol showed the same partial protection.
Different results were obtained when calcium (50 µM) and carboxyatractyloside (20 µM) were used. Again, the incubation of both compounds with mitochondria caused a reduction in the mitochondrial content of P-SH groups, once more with a small decrease observed in the presence of calcium (50 µM). Carvedilol did not show any protection against the decrease of P-SH groups, despite the observed complete inhibition with cyclosporin-A (panel C).
To determine if the observed reduction of mitochondrial DY induced by carvedilol (18, 20) could be inhibitory for calcium entry into mitochondria, we determined the calcium uptake rate and amplitude for several carvedilol concentrations. Values are presented as a percentage of control, as there were some fluctuations of control values and hence the need to normalize the data. As seen in Fig. 4 , the carvedilol concentration used in this study (20 µM) was without effect in the total amount of accumulated calcium A calcium (Ca) pulse of 100 µM was added. After 1 min, 1 mM tBHP was added to the mitochondrial suspension. 20 µM carvedilol (CV) and 1 µM cyclosporin-A (CyA) were added before calcium addition. * = p < 0.05 vs Ca + tBHP + CV and vs Ca + tBHP + CyA, ** = p < 0.005 vs control, *** = p < 0.001 vs control, n = 5. Panel C: A 50 µM calcium (Ca) pulse was added before the addition of 20 µM carboxyatractyloside (CX). 20 µM carvedilol (CV) and 1 µM cyclosporin-A (CyA) were added before calcium addition. * = p < 0.05 vs control, ** = p < 0.005 vs Ca and vs Ca + CX + CyA, *** = p < 0.001 vs Ca + CX + CyA, n = 5.
Humana Press Volume 4, 2004 (panel A), although there was an inhibitory outcome in the rate of calcium entry (panel B). Regarding total accumulated calcium, 30 µM carvedilol was observed to negatively affect that parameter. In the concentrations tested, tBHP and carboxyatractyloside did not induce the MPT in the absence of calcium (data not shown). Although we measured a small but significant reduction in the P-SH content (Fig. 3, panels B and C) , the calcium amount that was used in conjugation with tBHP and carboxyatractyloside was not enough to induce MPT-dependent mitochondrial depolarization (measured with a tetraphenylphosphonium-selective electrode; data not shown).
Discussion
In this work, three different MPT inducers were used to verify whether the antioxidant properties of carvedilol, as previously proposed (20), were crucial for the negative impact of carvedilol on the MPT. The results would be important to distinguish between specific carvedilol antioxidant-related effects in detriment to nonspecific effects on mitochondrial membranes or other pore component.
The classic MPT-inducing system calcium and phosphate was proposed to induce the pore by increasing the rate of mitochondrial reactive oxygen species (ROS) and oxidation of exposed thiol groups in proteins of the pore complex (4). In the presence of hydroperoxides as tert-butylhydroperoxide (tBHP), a lower threshold of calcium is necessary to induce the MPTP. Hydroperoxides are proposed to modulate the redox state of pyridine nucleotides via the glutathione peroxidase/reductase system (25,26), inducing a calcium-dependent permeability transition when changes in the mitochondrial pools of both reduced pyridine nucleotides and reduced glutathione occur. It was proposed that the MPTP was modulated by oxidative agents through both reduced pyridine nucleotides and glutathione at two separate sites (27) .
Finally, carboxyatractyloside is an inhibitor of the ANT, stabilizing the nucleotide-binding site in the cytoplasmic side of the inner membrane, a conformation described as being stimulatory for pore opening (28) . Thus, MPT induction by carboxytractyloside relies on a structural change of one pore component and not on primary oxidations of mitochondrial P-SH on any other protein component.
Our results showed that carvedilol was effective only (although not fully) against the MPT induced by calcium plus phosphate and calcium plus t-butylhydroperoxide. As expected, cyclosporin-A, the known MPTP inhibitor (29) , inhibited the MPT induction, which was seen by a total inhibition of DY depolarization (data not shown), swelling, and calcium-induced calcium release from heart mitochondria. The lower degree of protection afforded by carvedilol in calcium-induced calcium release (as measured by the fluorescent probe Calcium Green) can be ascribed to the reduced effect of that drug in the low-conductance Fig. 4 . Effect of carvedilol on mitochondrial calcium uptake (panel A, total accumulation; panel B, rate of calcium accumulation). Experiments were conducted using a calcium-sensitive fluorescent probe and as described under the Materials and Methods section. Heart mitochondria were allowed to accumulate calcium from a 100 µM pulse. Control values were around 120 nmol/mg protein for the amount of mitochondrial calcium uptake and 1.8 nmol/s/mg protein for the rate of mitochondrial calcium uptake. Carvedilol was preincubated for three minutes with the mitochondrial suspension. * = p < 0.05 vs control, ** = p < 0.01 vs control, n = 4.
state of the MPTP (20) . This protection would not avoid most of the MPTP-associated depolarization and calcium release. In fact, we verified a complete lack of protection by carvedilol on MPT-induced depolarization with any of the three inducers (data not shown-determined by using a tetraphenylphosphonium-selective electrode), which also confirmed our previous results (20) .
Not without surprise, we verified that the oxidation of P-SH groups by calcium plus phosphate and calcium plus t-BHP was only partly inhibited by cyclosporin-A. In opposition, total inhibition in the reduction of P-SH groups by cyclosporin-A was attained using carboxyatractyloside plus calcium as MPT inducers. As cyclosporin-A inhibits the MPT with a mechanism that is not antioxidant in nature (29), our results suggest that the calcium plus carboxyatractyloside-induced decrease in P-SH was a consequence and not a primary event in the MPT process. Cyclosporin-A-induced inhibition of P-SH oxidation never achieved control values when calcium plus phosphate or calcium plus tBHP were used. This finding suggests that part of the P-SH decay is a primary event (the MPT trigger) and not a consequence of MPT opening. Thiol oxidation as a consequence of MPT induction could be originating from membrane depolarization itself (30) , indirectly via the depressed activity of the mitochondrial potential-driven transhydrogenase (6), or even by the loss of reduced cofactors (GSH, NADPH, NADH) via the open pores (8) . We can also anticipate that loss of cytochrome c upon outer membrane rupture may contribute to a secondary burst of oxygen free radicals.
The differential effect of both cyclosporin-A and carvedilol against the MPT induced by carboxyatractylate is the key result in our discussion. Cyclosporin-A inhibited the P-SH reduction secondary to MPTP induction with antioxidant-independent mechanisms, while carvedilol may partly inhibit the primary P-SH decay considered the trigger for MPT induction owing to its antioxidant properties (13, 14, 20) . The lack of protection afforded by carvedilol against membrane permeabilization after MPT induction rules out the prevention of P-SH oxidation derived from DY loss (although some protection derived from less significant damage to the outer membrane or decreased loss of reduced cofactors from the mitochondrial matrix could be also attained).
The inhibitory effect of carvedilol in the highconductance state of the MPTP can indeed correlate with the degree of protection afforded by carvedilol on mitochondrial P-SH groups. Because a full inhibition of P-SH oxidation was not obtained in the presence of carvedilol, the low conductance state of the MPTP would still be present, thus explaining the lack of inhibition in the DY depolarization (31) and the reduced prevention against calcium-induced calcium release.
Calcium concentrations used in conjugation with tBHP and carboxyatractyloside were unable to cause MPT-dependent mitochondrial depolarization (data not shown), although we measured a small but significant reduction in the P-SH content (Fig. 3 , panels B and C). This finding expresses the concept of the thiol oxidation threshold for pore opening. Despite the significant reduction in the P-SH pool, we hypothesized that the thiol oxidation threshold for pore opening was still uncrossed.
Another possible explanation for the protective effect of carvedilol would be a reduction in calcium entry owing to carvedilol protonophoretic activity (18) . The data taken from Fig. 4 allowed us to conclude that in the concentrations tested in this study, carvedilol, had no effect on the amount of calcium loaded into mitochondria (although we cannot rule out that a decreased calcium entry may be attainable in vivo), Nevertheless, a slower rate of calcium entry was observed. One may think that the decreased rate of calcium entry would be inhibitory for pore opening. However, it has already been shown that slower mitochondrial calcium uptake results in massive calcium overload without significant changes in matrix pH, causing an opening of the MPTP in its highconductance form (11) . Thus, the carvedilol-induced effect in mitochondrial calcium uptake would be prone to pore induction, not to the opposite effect. Apparently, the decreased calcium rate accumulation and membrane DY depolarization promoted by carvedilol had no stimulatory effect in the high conductance state of the MPTP. We also verified that the carvedilol-induced small DY decrease had no direct effect on pore opening (data not shown), as the pore was described as being voltage-gated (32) .
The main conclusion from this work is that carvedilol is effective only against compounds that induce the MPT because of thiol-oxidizing mechanisms.
This conclusion confirms our previous ideas (20) and indicates that carvedilol may not be effective against MPT effectors that are not primarily dependent on P-SH oxidation. Nevertheless, we must acknowledge that a limiting factor in our study is the assumption of a singular and direct effect of carvedilol on the mitochondrial transition pore. Nevertheless, we have no reason to include any other interactions that could contribute for the observed results.
The antioxidant-related protection of carvedilol against the deleterious form of the MPTP has clinical implications, namely in the maintenance of mitochondrial integrity and inhibition of cytochrome-c release through external membrane rupture after large amplitude swelling. Also, protein deactivation by thiol crosslinking would be hindered by carvedilol, and restoration of mitochondrial DY would be possible in the absence of severe mitochondrial structural damage. Inhibition of MPTP-dependent apoptosis triggering by carvedilol may be one of the faces of carvedilol-afforded protection against ischemic heart disease. The plasma peak concentration of carvedilol in human volunteers was reported to be 0.3 µM after an oral dose of 50 mg (16) . Carvedilol is a highly lipophilic compound with a partition coefficient (log P octanol-H 2 O) of 3.4, which is similar to that of propranolol (13) . It is meaningful that the concentration of propranolol in Purkinje fibers and platelets reached concentrations up to 30-40-fold higher than plasma concentrations (33) . Additionally, carvedilol shows a large distribution volume in humans, indicating that the drug is extensively distributed to the tissue (34) . A recent investigation suggested that in lipids moieties, the drug reaches concentrations ranging from approx 6-69 µM (35) . Therefore, it is quite conceivable that an effective level of carvedilol capable of protecting mitochondrial function (10-20 µM) may be attained in vivo, which gives clinical relevance to the effects described in this paper. 
